Screening In Anticipation of Future Research
- Study HIC#:2000021443
- Last Updated:10/26/2021
This is a blood test screening protocol to test for the human immunodeficiency virus (HIV), Hepatitis B (HBV), and Hepatitis C (HCV) infection in anticipation of future research on the blood through the Yale Liver Center Patient Registry and Serum/Tissue Bank. The tests are required because the researchers need to know that the samples are safe to handle and because these viruses can change how the cells in your blood work and they may then not be truly representative of the cells that researchers are studying.
- Age2 years - 17 years
- Start Date10/25/2017
- End Date12/31/2022
Trial Purpose and Description
This screening protocol proposes to test blood samples for HIV, hepatitis B and hepatitis C infection status of patients consenting to participate in the Yale Liver Center Patient Registry and Serum/Tissue Bank (HIC protocol # 0603001208). Subjects are selected for having or being at risk for rare liver disease or liver disorder genetically caused (e.g., cystic fibrosis) or involving altered immunity or for their willingness to serve as healthy controls.
The Yale Liver Center Patient Registry and Specimen Bank is hereafter referred to as the Registry and Bank.
Healthy adults to act as controls (comparison to others who do have a medical issue). Also, children 2 to 17 years old and adults who are at risk of or have any of the following rare liver disease or liver disorders genetically caused or involving altered immunity including primary sclerosing cholangitis, primary biliary cholangiopathy, cystic fibrosis, progressive familial intrahepatic cholestasis, Wilson's disease, biliary atresia, congenital hepatic fibrosis, Caroli disease, polycystic liver diseases or other congenital/metabolic liver disease including undiagnosed biliary disease.